Physicians' Academy for Cardiovascular Education

Adequate BP measurement depends more on proper technique than unattended measurement

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Restrictive transfusion is non-inferior to liberal approach during cardiac surgery

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - David Mazer - Toronto, Ont, Canada

Analogous to LDL-c, the lower the better also seems true for inflammation

Nov. 14, 2017 - Paul Ridker, Boston, MA, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Cardiovascular protection in type 2 diabetes

Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

Aug. 27, 2017

Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz

Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Insights from the first trials in epigenetics in human: What is the way forward?

Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017

Heart failure & Diabetes: Time for a more unified approach

Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Brief update on the LEADER cardiovascular outcomes trial

Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Treatment of patients on oral anticoagulation who present with ACS

Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

High-intensity statin therapy reduces CV events in Japanese CAD patients

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Hiroaki Shimokawa (Tohoku University, Sendai, Japan)

Nov. 15, 2017 - news

AHA 2017 The REAL-CAD trial demonstrated that CV events and overall mortality were reduced by pitavastatin compared to low-intensity statin treatment in Japanese stable CAD patients.

Baseline risk of outcomes does not predict the treatment effect of GLP-1 receptor agonist

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Robert J. Mentz (Duke University, Durham, NC, USA)

Nov. 15, 2017 - news

AHA 2017 An analysis of the EXSCEL trial examined whether risk at baseline predicted the effect of exenatide on mortality and MACE.

SGLT-2 inhibition reduces mortality and hospitalization for HF in patients with diabetes and PAD

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Subodh Verma (St Michael's Hospital, University of Toronto, Canada)

Nov. 15, 2017 - news

AHA 2017 A sub-analysis of the EMPA-REG OUTCOME examined whether the benefits of empaglifozin are preserved in diabetic patients with and without PAD.

Adequate BP measurement depends more on proper technique than unattended measurement

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA
In the SPRINT tiral, BP measurement was not always conducted in the absence of a physician or nurse. A posthoc analysis evaluated whether this affected the results.

AHA 2017 In the SPRINT tiral, BP measurement was no always conducted i nthe absence of a physician or nurse. A posthoc analysis evaluated whether this affected the results.

Restrictive transfusion is non-inferior to liberal approach during cardiac surgery

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - David Mazer - Toronto, Ont, Canada
Comparison of two triggers for RBC transfusion showed that a restrictive strategy was non-inferior to a liberal transfusion approach in moderate to high risk patients.

AHA 2017 Comparison of two triggers for RBC transfusion showed that a restrictive strategy was non-inferior to a liberal transfusion approach in moderate to high risk patients.

Analogous to LDL-c, the lower the better also seems true for inflammation

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - Paul Ridker, Boston, MA, USA
A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but respons to treatment did.

AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but respons to treatment did.

New ACC/AHA Hypertension Practice Guidelines stress lifestyle improvement and lower SBP target

Nov. 14, 2017 - news
The new guidelines now define hypertension as >130/80 mmHg, emphasize the need for lifestyle changes and specify details of accurate BP measurement methods.

AHA 2017 The new guidelines now define hypertension as >130/80 mmHg, emphasize the need for lifestyle changes and specify details of accurate BP measurement methods.

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.
A lot of variation in BP measurement methods were seen in SPRINT, despite the protocol, but in 3/4 of sites patients were alone at least at some point during the BP reading.

AHA 2017 A lot of variation in BP measurement methods were seen in SPRINT, despite the protocol, but in 3/4 of sites patients were alone at least at some point during the BP reading.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA
Paul Whelton, chair of the 2017 Hypertension Practice Guidelines, summarises the major changes as compared with the previous guideline.

AHA 2017 Paul Whelton, chair of the 2017 Hypertension Practice Guidelines, summarises the major changes as compared with the previous guideline.

Presence of staff does not affect CVD risk reduction in intensively treated SPRINT group

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Karen C. Johnson (University of Tennessee Health Science Center, Memphis, TN, US)

Nov. 14, 2017 - news

AHA 2017 A post-hoc survey of the SPRINT examined whether the presence or absence of physician or nursing during the BP measurement changed the treatment effect.

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Bariatric surgery induced remission of hypertension in obese patients and diminishes medication

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Carlos Schiavon (Heart Hospital, Sao Paulo, Brazil

Nov. 14, 2017 - news

AHA 2017 Gastric bypass in obese hypertensives (BMI 30-39.9) led to stable BP and reduction of medication need in the majority of patients, and about half showed remission after 1 year.

Agenda